Literature DB >> 14576116

Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis.

M A Zeitlinger1, P Dehghanyar, B X Mayer, B S Schenk, U Neckel, G Heinz, A Georgopoulos, M Müller, C Joukhadar.   

Abstract

Antimicrobial therapy of soft tissue infections in patients with sepsis sometimes lacks efficiency, despite the documented susceptibility of the causative pathogen to the administered antibiotic. In this context, impaired equilibration between the antibiotic concentrations in plasma and those in tissues in critically ill patients has been discussed. To characterize the impact of tissue penetration of anti-infective agents on antimicrobial killing, we used microdialysis to measure the concentration-versus-time profiles of levofloxacin in the interstitial space fluid of skeletal muscle in patients with sepsis. Subsequently, we applied an established dynamic in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate bacterial killing at the site of infection. The population mean areas under the concentration-time curves (AUCs) for levofloxacin showed that levofloxacin excellently penetrates soft tissues, as indicated by the ratio of the AUC from time zero to 8 h (AUC(0-8)) for muscle tissue (AUC(0-8 muscle)) to the AUC(0-8) for free drug in plasma (AUC(0-8 plasma free)) (AUC(0-8 muscle)/AUC(0-8 plasma free) ratio) of 0.85. The individual values of tissue penetration and maximum concentration (C(max)) in muscle tissue were highly variable. No difference in bacterial killing of a select Staphylococcus aureus strain for which the MIC was 0.5 microg/ml was found between individuals after exposure to dynamically changing concentrations of levofloxacin in plasma and tissue in vitro. In contrast, the decrease in the bacterial counts of Pseudomonas aeruginosa (MIC = 2 microg/ml) varied extensively when the bacteria were exposed to levofloxacin at the concentrations determined from the individual concentration-versus-time profiles obtained in skeletal muscle. The extent of bacterial killing could be predicted by calculating individual C(max)/MIC and AUC(0-8 muscle)/AUC(0-8 plasma free) ratios (R = 0.96 and 0.93, respectively). We have therefore shown in the present study that individual differences in the tissue penetration of levofloxacin may markedly affect target site killing of bacteria for which MICs are close to 2 microg/ml.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576116      PMCID: PMC253769          DOI: 10.1128/AAC.47.11.3548-3553.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Target site concentrations of ciprofloxacin after single intravenous and oral doses.

Authors:  Martin Brunner; Heino Stabeta; Jan-Georg Möller; Claudia Schrolnberger; Boban Erovic; Ursula Hollenstein; Markus Zeitlinger; Hans Georg Eichler; Markus Müller
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

2.  The ACCP-SCCM consensus conference on sepsis and organ failure.

Authors:  R C Bone; W J Sibbald; C L Sprung
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

3.  Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.

Authors:  J J Schentag; D E Nix; M H Adelman
Journal:  DICP       Date:  1991-10

4.  A microdialysis method allowing characterization of intercellular water space in humans.

Authors:  P Lönnroth; P A Jansson; U Smith
Journal:  Am J Physiol       Date:  1987-08

5.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

6.  In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.

Authors:  Mayumi Tanaka; Emi Yamazaki; Megumi Chiba; Kiyomi Yoshihara; Takaaki Akasaka; Makoto Takemura; Kenichi Sato
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

7.  Predominant pathogens in hospital infections.

Authors:  W R Jarvis; W J Martone
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

8.  Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis.

Authors:  Christian Joukhadar; Nikolas Klein; Bernhard X Mayer; Nicole Kreischitz; Georg Delle-Karth; Peter Palkovits; Gottfried Heinz; Markus Müller
Journal:  Crit Care Med       Date:  2002-07       Impact factor: 7.598

9.  Pharmacokinetics of antibiotics in critically ill patients.

Authors:  R van Dalen; T B Vree
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

10.  In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa.

Authors:  David S Burgess; Ronald G Hall; Thomas C Hardin
Journal:  Diagn Microbiol Infect Dis       Date:  2003-06       Impact factor: 2.803

View more
  24 in total

1.  Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy.

Authors:  S Krasniqi; P Matzneller; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

Review 2.  Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future.

Authors:  Christian Joukhadar; Markus Müller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses.

Authors:  Pejman Dehghanyar; Cornelia Bürger; Markus Zeitlinger; Florian Islinger; Florian Kovar; Markus Müller; Charlotte Kloft; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

Review 4.  Lung microdialysis--a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review).

Authors:  Markus Zeitlinger; Markus Müller; Christian Joukhadar
Journal:  AAPS J       Date:  2005-10-22       Impact factor: 4.009

5.  Clinical scoring system for the prediction of target site penetration of antimicrobials in patients with sepsis.

Authors:  Barbara S Zeitlinger; Markus Zeitlinger; Irmgard Leitner; Markus Müller; Christian Joukhadar
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery.

Authors:  Doris Hutschala; Keso Skhirtladze; Andreas Zuckermann; Wilfried Wisser; Peter Jaksch; Bernhard Xaver Mayer-Helm; Heinz Burgmann; Ernst Wolner; Markus Müller; Edda M Tschernko
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 7.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

Review 8.  A comprehensive review on the pharmacokinetics of antibiotics in interstitial fluid spaces in humans: implications on dosing and clinical pharmacokinetic monitoring.

Authors:  Tony K L Kiang; Urs O Häfeli; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

9.  Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.

Authors:  Iris K Minichmayr; André Schaeftlein; Joseph L Kuti; Markus Zeitlinger; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

10.  Tissue pharmacokinetics of levofloxacin in human soft tissue infections.

Authors:  Romuald Bellmann; Gerald Kuchling; Pejman Dehghanyar; Markus Zeitlinger; Erich Minar; Bernhard X Mayer; Markus Müller; Christian Joukhadar
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.